You are here: Industry Insights > Biotechnology

News List

AzarGen Presents AZprom™ - Superior Synthetic Promotors to Enhance Molecular Farming Applications Biotech Newswire
July 10, 2024
AzarGen presents AZprom™ - Superior Synthetic Promotors and it shows a dramatic increase in the expression of fluorescent proteins, outperforming the ‘double-enhancer’ CaMV 35S promoter more than 5-fold in transgenic tobacco plants.
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards PharmaSources
March 27, 2024
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents.
International Perspective, Cutting-edge Technology Learning - Entering into HongKe(虹科) Technology Co., Ltd. PharmaSources.com
May 27, 2022
HongKe(虹科) Technology Co., Ltd., established in 2007 (previously HongKe(宏科) founded in 1995), is headquartered in Guangzhou, the economic and cultural center of southern China.
Discovering Biotechnology: Top 9 Chinese Pharmaceutical Companies in 2020 Deborah Seah
November 04, 2020
China 's pharmaceutical industry garnered a total revenue of about 2.6 trillion yuan in 2019 amounting to an eight percent year-on-year growth.
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions PR NEWSWIRE
November 20, 2024
Rona Therapeutics presented positive results from the Phase 1 clinical trial of RN0191 at the American Heart Association's (AHA) Annual Scientific Sessions in Chicago, IL, November 16th, 2024.
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics B3CNewswire
January 05, 2024
On January 4, 2024, Beijing time, Allorion Therapeutics announced that it has entered into a transfer agreement with Avenzo Therapeutics, Inc. (Avenzo) of the United States
Vetter’s European Clinical Site Receives Permanent Manufacturer’s Authorization B3C newswire
November 16, 2023
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria.
High Demand: Vetter Expands Production Capacities and Services Offered at Its Austrian Site PharmaSources
May 10, 2023
Vetter has completed the first year of production in Rankweil successfully and is preparing to further increase production capacities and capabilities on site.
Biotech and pharma services outsourcing market to be worth over $91bn by 2028 europeanpharmaceuticalreview
April 14, 2021
A new report suggests the global biotechnology and pharmaceutical services outsourcing market will grow because of the pandemic and rising drug development costs and R&D investments.
Thailand BOI Okays Biotech Projects Worth 2.4 Bln Baht in Total Investment prnasia
April 08, 2021
The Thailand Board of Investment (BOI) said it has recently approved new projects in the field of advanced biotechnology, worth a combined 2.4 billion baht (around USD78 million) in investment, reflecting the increased interest of local and foreign ...

Previous page 1 2 3 4 5 6 Next page